Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PaxVax
Vaccines
Themis’ chikungunya vaccine nabs fast FDA review
Themis' win comes after the FDA granted the same designation to chikungunya candidates from PaxVax and Valneva.
Angus Liu
Feb 26, 2019 11:57am
Themis eyes phase 3 for chikungunya vaccine
Nov 7, 2018 10:10am
Acquisitive Emergent BioSolutions buys PaxVax for $270M
Aug 13, 2018 12:25pm
FDA places PaxVax's phase 2 chikungunya shot on its fast track
May 8, 2018 3:57pm
Themis nabs €10M series C for chikungunya, Zika push
Jan 9, 2018 3:09pm
ImmusanT, PaxVax and more—News of Note
Nov 14, 2017 2:49pm
